Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines

The Prostate
Neal D ShoreRaoul Concepcion

Abstract

For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well-described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The risk-benefit analysis for initiating ADT in PC patients throughout the PC disease continuum warrants review. A 14-member panel comprised of urologic and medical oncologists were chosen for an expert review panel, to provide guidance on a more judicious use of ADT in advanced PC patients. Panel members were chosen based upon their academic and community experience and expertise in the management of PC patients. Four academic members of the panel served as group leaders; the remaining eight panel members were from Large Urology Group Practice Association practices with proven experience in leading their advanced PC clinics. The panel members were assigned to four separate working groups, and were tasked with addressing the role of ADT in specific PC settings. This article describes the practical recommendations of an expert panel for the use of ADT throughout the PC disease co...Continue Reading

References

May 11, 1999·JAMA : the Journal of the American Medical Association·C R PoundP C Walsh
Sep 29, 2001·The New England Journal of Medicine·M R SmithJ S Finkelstein
Dec 18, 2001·The Journal of Urology·Mark S SolowayUNKNOWN Lupron Depot Neoadjuvant Prostate Cancer Study Group
Aug 13, 2003·The Journal of Urology·L H KlotzUNKNOWN Canadian Uro-Oncology Group
Mar 18, 2004·JAMA : the Journal of the American Medical Association·Andrew J StephensonKevin M Slawin
Apr 8, 2004·Current Opinion in Urology·Jeffrey M HolzbeierleinJ Brantley Thrasher
Sep 24, 2004·International Journal of Radiation Oncology, Biology, Physics·Charmaine Kim-SingUNKNOWN Prostate Cohort Outcomes Initiative
Jan 14, 2005·The New England Journal of Medicine·Vahakn B ShahinianJames S Goodwin
Apr 9, 2005·International Journal of Radiation Oncology, Biology, Physics·Miljenko V PilepichDavid Grignon
Jan 25, 2006·BJU International·David G McLeodUNKNOWN Casodex Early Prostate Cancer Trialists' Group
Jun 6, 2006·The Lancet Oncology·Edward M MessingUNKNOWN Eastern Cooperative Oncology Group study EST 3886
Sep 20, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nancy L KeatingMatthew R Smith
Apr 4, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D Andrew LoblawUNKNOWN American Society of Clinical Oncology
Oct 11, 2007·Journal of the National Cancer Institute·Henry K TsaiPeter R Carroll
Mar 4, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard I ScherUNKNOWN Prostate Cancer Clinical Trials Working Group
Jul 10, 2008·JAMA : the Journal of the American Medical Association·Grace L Lu-YaoSiu-Long Yao
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yu-Ning WongKatrina Armstrong
Apr 17, 2009·European Urology·Yu-Ning WongKatrina Armstrong
Jun 10, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shabbir M H AlibhaiLawrence F Paszat
Jun 12, 2009·The New England Journal of Medicine·Michel BollaUNKNOWN EORTC Radiation Oncology Group and Genito-Urinary Tract Cancer Group
Dec 10, 2009·Journal of the National Cancer Institute·Nancy L KeatingMatthew R Smith
Sep 22, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ryan M FrankeAlex Sparreboom
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tanya B DorffL Michael Glode
Jul 15, 2011·The New England Journal of Medicine·Christopher U JonesWilliam U Shipley
Aug 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip J SaylorMatthew R Smith
Dec 8, 2011·JAMA : the Journal of the American Medical Association·Paul L NguyenToni K Choueiri
Aug 31, 2012·The New England Journal of Medicine·Juanita M CrookLaurence Klotz
Apr 5, 2013·The New England Journal of Medicine·Maha HussainIan M Thompson
May 28, 2013·The Journal of Urology·Ian M ThompsonMartha M Faraday

❮ Previous
Next ❯

Citations

Mar 28, 2021·Proceedings of the National Academy of Sciences of the United States of America·Wan-Fu WuJan-Ake Gustafsson
Apr 19, 2021·Current Treatment Options in Oncology·Azariyas A ChallaAvirup Guha
Sep 24, 2021·Aktuelle Urologie·Stefan ZastrowHenrik Suttmann

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Clinical Trials Mentioned

NCT00936390

Software Mentioned

STAMPEDE
FRAX Fracture Risk Assessment Tool
LATITUDE

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.